Unilabs, a leading diagnostics company in Europe, and Natera, a leading innovator in prenatal genetic testing, announced today that Unilabs will distribute Natera’s non-invasive prenatal screening test, Panorama™, across its wide network in Switzerland and Scandinavia.
Natera, a leading innovator in prenatal genetic testing, and Echevarne, a leading clinical analysis laboratory in Spain, today announced the signing of a distribution agreement for Echevarne to offer Natera’s non-invasive prenatal screening test (NIPT), Panorama™, through its facilities in Spain.
Ab sofort wird die amedes Gruppe den Natera-Test für nicht-invasive Pränataldiagnostik in Deutschland vertreiben. amedes, bundesweit tätiger diagnostischer Dienstleister, teilte heute den Vertragsabschluss mit der US-amerikanischen Diagnostikfirma mit. Der Panorama TM – Test wird bereits in den USA
Financing Adds Leading Growth Stage Investors to Existing Syndicate Natera today announced that it has completed a $54.6 million financing round to support the expansion and continued global rollout of Natera’s non-invasive prenatal test, Panorama™. The financing round included two new lead
Blinded, Independent Study Shows Proprietary Technology Accurately Detected Trisomy 21, Trisomy 13, Trisomy 18, Monosomy X and Triploidy The Fetal Medicine Foundation and Natera today announced the publication of data in Prenatal Diagnosis demonstrating the high accuracy of Natera’s non-invasive
ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory, and Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that Natera's non-invasive prenatal screening test, Panorama™, is available to ARUP clients nationwide.
Bio-Reference Laboratories, Inc. (BRLI) announced today that the Company and Natera have entered into a definitive agreement to commercialize the Panorama(TM) non-invasive prenatal screening test developed by Natera. The Panorama test will be sold by the GenPath business unit of Bioreference.
Quest Diagnostics (NYSE:DGX), the world’s leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera.
Panorama’s clinical validation data was presented live at the annual Society of Maternal Fetal Medicine Meeting on February 15, 2013. Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that the company’s non-invasive prenatal screening test, Panorama™, will
Data Presented at Society for Maternal-Fetal Medicine Annual Meeting Natera today announced the presentation of validation data demonstrating unmatched specificity and sensitivity of the company's non-invasive prenatal test, Panorama(TM). The presentation, titled "Use of targeted sequencing of SNPs